TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04008979

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin - lipid complex

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin - lipid complex

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin - lipid complex

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin - lipid complex
Study: NCT03437148

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Innocor®
Description: Inert gas rebreathing device: Innocor® (Innovision, Odense, Denmark)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physioflow®
Description: Bioimpedance cardiograph: Physioflow® (Manatec, France)
Study: NCT03127137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Experimental Group 1 triamcinolone and lidocaine
Description: Experimental Group 1 will receive Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL 1% lidocaine (total volume 4 cc)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Experimental Group 2 triamcinolone and saline
Description: Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL preservative saline (total volume 4 cc)
Study: NCT03709862

Intervention type: DIAGNOSTIC_TEST
Intervention: Whole Genome Sequencing
Description: Residual DNA from clinical samples will be utilised for whole genome sequencing of Treponema pallidum the causative agent of syphilis
Study: NCT00684671

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Twinrix
Description: Intramuscular injection, single dose in left deltoid.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B
Description: Intramuscular injection, single dose in left deltoid.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix
Description: Intramuscular injection, single dose in right deltoid.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HBVAXPRO
Description: Intramuscular injection, single dose in the left deltoid.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaqta
Description: Intramuscular injection, single dose in right deltoid.
Study: NCT00113425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V-Beam laser, Candela Corp., 595 nm wavelength
Description: Subjects will receive a series of up to 6 laser therapy sessions with a treatment interval of from approximately 1 to 4 weeks. In all cases, laser treatment parameters will be within the guidelines normally used clinically with the V-Beam laser, and thus fluences used will not exceed 15 J/cm2.
Study: NCT06266962

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Atropine drops
Description: Patients administered 1% Atropine drops twice a day for a week before the cataract surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Patients underwent the instillation of epinephrine into the anterior chamber at the beginning of the cataract surgery.
Study: NCT03392298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colla corii asini
Description: 15g Colla corii asini granule, once daily for 4 weeks
Study: NCT04182971

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fruit
Description: Phase 1 is 227g of orange fruit, Phase 2 is 230g of apple fruit

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fruit juice
Description: Phase 1 is 250g of orange juice, Phase 2 is 235g of apple juice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruit juice plus fiber
Description: Phase 1 is 157g of orange juice + 100g of orange pomace fiber (39% pomace by weight), Phase 2 is 129g of apple juice + 106g of apple pomace fiber (45% pomace by weight)
Study: NCT00438828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 8mg Dexamethasone PO on days 0 (prior to radiation treatment), and days 1, 2, and 3 following radiation treatment.
Study: NCT02393040

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRP/Saline
Description: PRP/Saline: Two groups were defined: group A and group B. Group A received treatment with PRP on the right half-head and placebo on the left half-head while group B received administration of PRP on left half-head and placebo on the right half-head.~Same patient will be injected with PRP and a saline solution. Each patient will be injected on half-head.
Study: NCT04607720

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: artificial-EUS-FNA
Description: The ultrasound endoscopists manually determined the region of interest (ROI) according to CH-EUS, and punctured 2 needles in the tumor area with a 22G needle, and each needle moved 15-20 times back and forth in the lesion. After puncture, insert the needle core, rinse the needle with 0.1ml sterile saline, and further apply air flushing to ensure that each tissue is sent to the slide.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: artificial-EUS-FNA
Description: The ultrasound endoscopists manually determined the region of interest (ROI) according to CH-EUS, and punctured 2 needles in the tumor area with a 22G needle, and each needle moved 15-20 times back and forth in the lesion. After puncture, insert the needle core, rinse the needle with 0.1ml sterile saline, and further apply air flushing to ensure that each tissue is sent to the slide.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AI-EUS-FNA
Description: In the AI-assisted diagnosis system, the assisted targeting EUS-FNA unit is applied, and the ultrasound endoscopist selects the region of interest (ROI) according to the thermogram to perform targeted EUS-FNA puncture(2 needles in the same way).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AI-EUS-FNA
Description: In the AI-assisted diagnosis system, the assisted targeting EUS-FNA unit is applied, and the ultrasound endoscopist selects the region of interest (ROI) according to the thermogram to perform targeted EUS-FNA puncture(2 needles in the same way).
Study: NCT02012920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seviteronel: given orally once daily in 28 day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seviteronel: given orally once daily in 28 day cycles
Study: NCT01775592

Intervention type: DRUG
Group type: OTHER
Intervention: Arterakin (DHA-PPQ)
Study: NCT01315249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indacaterol and glycopyrronium (QVA149)
Description: QVA149 capsules delivered via dry powder inhaler (SDDPI), once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to fluticasone/salmeterol
Description: Placebo to fluticasone/salmeterol delivered via Accuhaler® device, twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone/salmeterol
Description: Fluticasone/salmeterol dry inhalation powder delivered via Accuhaler® device, twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to indacaterol and glycopyrronium (QVA149)
Description: Placebo to QVA149 delivered via dry powder inhaler (SDDPI), once daily
Study: NCT03955536

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group A: Group routine cardiac rehabilitation program (RCRP)
Description: Patient education, Chest Physiotherapy, Abdominal and chest breathing, Bronchial hygiene techniques, Segmental breathing exercises, Triflow, exercise and mobilization,graduated exercise, positioning, active joint movement, moving inside bed, sitting at the edge of the bed, transfer from bed to chair, standing walking program, up and down stairs.~Evaluations for each patient (preoperative and just before discharge) Spirometric measurements Intraoral pressure measurementDyspnea assessment (BORG), Pain assessment (VAS), Evaluation of anxiety and depression (HAD) Evaluation of functional capacity (6 minutes walking test) Quality of Life (MacNew Heart Disease Specific Quality of Life Questionnaire)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group B: Group RCRP and inspiratory muscle training
Description: use of additional virtual reality goggles in the routine cardiac rehabilitation program Virtual reality glasses installed in the patient will feel the best way to feel an environment.~Virtual reality glasses are planned to be used 15 minutes by increasing the usage period.~Evaluations for each patient (preoperative and just before discharge) Spirometric measurements Intraoral pressure measurementDyspnea assessment (BORG), Pain assessment (VAS), Evaluation of anxiety and depression (HAD) Evaluation of functional capacity (6 minutes walking test) Quality of Life (MacNew Heart Disease Specific Quality of Life Questionnaire)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group C: Group RCRP and virtual reality application
Description: nspiratory muscle training with Threshold for routine cardiac rehabilitation Training intensity~- 30% of the maximum measured inspiratory pressure per week (15 min.). Every 10 breaths after rest.~Evaluations for each patient (preoperative and just before discharge) Spirometric measurements Intraoral pressure measurementDyspnea assessment (BORG), Pain assessment (VAS), Evaluation of anxiety and depression (HAD) Evaluation of functional capacity (6 minutes walking test) Quality of Life (MacNew Heart Disease Specific Quality of Life Questionnaire)
Study: NCT02696681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Integrating CBT for mental health and substance issues concern with CBT for health behavior change
Study: NCT03174119

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Light therapy - active
Description: Active light will be used for one week, as compared to placebo light.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo light
Description: Placebo light will be used for one week, as compared to real light exposition.
Study: NCT00870870

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000 milligrams per square meter (mg/m\^2) on Days 1 and 8 of each cycle~\[First 6 cycles (18 weeks)\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 milligrams per square meter (mg/m\^2) on Days 1 and 8 of each cycle~\[First 6 cycles (18 weeks)\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75 mg/m\^2 on Day 1 of each cycle~\[First 6 cycles (18 weeks)\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m\^2 on Day 1 of each cycle~\[First 6 cycles (18 weeks)\]

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12 (cixutumumab)
Description: 6 milligrams per kilogram (mg/kg) intravenous (IV) infusion, administered once per week (on Days 1, 8, and 15 of each cycle)~\[First 6 cycles (18 weeks)\]

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: 400 mg/m\^2 IV infusion, administered on Day 1 of Cycle 1, 250 mg/m\^2 once per week thereafter~\[First 6 cycles (18 weeks)\]

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 400 mg/m\^2 IV infusion, administered on Day 1 of Cycle 1, 250 mg/m\^2 once per week thereafter~\[First 6 cycles (18 weeks)\]

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12 (cixutumumab)
Description: 10 mg/kg IV infusion, administered once every 2 weeks~(Maintenance therapy)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: 500 mg/m\^2 IV infusion, administered once every 2 weeks~(Maintenance therapy)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 500 mg/m\^2 IV infusion, administered once every 2 weeks~(Maintenance therapy)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Area under the curve (AUC) = 5, Day 1 of each cycle~\[First 6 cycles (18 weeks)\]~\*Carboplatin will be replaced by Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Area under the curve (AUC) = 5, Day 1 of each cycle~\[First 6 cycles (18 weeks)\]~\*Carboplatin will be replaced by Cisplatin
Study: NCT02354742

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Echo guided fluid resuscitation
Description: Patients will have their fluid resuscitation care guided by measurements obtained during an echo.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EGDT fluid resuscitation
Description: Patients will have their fluid resuscitation care guided by an EGDT protocol, which is currently used as standard of care.
Study: NCT03025607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JOOL Health Mobile Phone Application
Description: JOOL Health is a mobile phone-based application that aims to increase autonomous motivation to prevent T2DM by helping individuals make connections between certain health behaviors and the energy and willpower needed to achieve personal goals. On a daily basis, JOOL Health users chart the following health behaviors: Sleep, Presence, Activity, Creativity, and Eating. On a weekly basis, JOOL Health users are asked to record how well they lived according to their purpose and values. Through the integration of user-entered information with contextual data, JOOL Health provides tailored messaging and daily predictions of individuals' energy and willpower.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JOOL Health Mobile Phone Application
Description: JOOL Health is a mobile phone-based application that aims to increase autonomous motivation to prevent T2DM by helping individuals make connections between certain health behaviors and the energy and willpower needed to achieve personal goals. On a daily basis, JOOL Health users chart the following health behaviors: Sleep, Presence, Activity, Creativity, and Eating. On a weekly basis, JOOL Health users are asked to record how well they lived according to their purpose and values. Through the integration of user-entered information with contextual data, JOOL Health provides tailored messaging and daily predictions of individuals' energy and willpower.
Study: NCT04033809

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multigrain powder (S)
Description: A twice daily high fiber multigrain powder supplementation for 12 weeks
Study: NCT01365650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Description: Single intranasal dose of 30 mg ketorolac tromethamine (one 15 mg spray into each nostril) on Day 1 of Period 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline Hydrochloride
Description: Single intranasal dose of oxymetazoline hydrochloride followed by a single intranasal dose of 30 mg ketorolac tromethamine (one 15 mg spray into each nostril) 30 minutes later on Day 1 of Period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate
Description: Seven days of treatment with intranasal fluticasone propionate (between Periods 2 and 3) followed by a single intranasal dose of 30 mg ketorolac tromethamine (one 15 mg spray into each nostril) on Day 1 of Period 3
Study: NCT00841100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kuvan
Description: 20mg/kg by mouth once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kuvan
Description: 20mg/kg by mouth once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kuvan
Description: 20mg/kg by mouth once daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Phenylalanine-restricted diet (4-10 mg/kg/day phenylalanine) using the prescribed phenylalanine-free medical formula and low protein foods tested with the patients for taste and acceptance to lower blood phenylalanine levels below 600 umol/l.
Study: NCT03107468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mokhuri intensive treatment
Description: Patients in this arm will be treated with acupuncture, Chuna and patient consultation during 5 weeks. For acupuncture therapy, disposable sterile needles will be placed on LI4, ST36, LV3, B22, B23, B24 and B25 of both sides of a patient for 15 minutes. For Chuna therapy, the patient lies on the Ergo Style™ FX-5820 Table in the prone position and back muscles will be relaxed by manual manipulation during flexion and extension movement of the table for 5 to 6 minutes. Patient consultation regarding the precautions for everyday life, the precautions for activity in bed, the precautions for walking, the precautions for particular movements and the exercises will be offered for 5 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical conventional standard treatment
Description: Patients in this arm will be treated with 10 sessions of non-surgical conventional standard treatment including conventional drug treatment and injection treatment under the consultation of neurosurgeons or doctors of anesthesiology or rehabilitation medicine during 5 weeks. For drug therapy, muscle relaxants, NSAIDs, gabapentin, pregabalin or tricyclic antidepressants will be prescribe. For epidural steroid injection, 3cc of epidurals will be injected at the affected lesion once or twice. For physical therapy, participants shall participate in conventional physical therapy with the aid of physical therapists, including heating pad, deep tissue heating device and transcutaneous electrical nerve stimulation (TENS) twice a week during the five weeks of participation.
Study: NCT04433390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol
Description: one naloxegol 12.5 mg tablet will be administrated 2 hours before surgery. One 25 mg naloxegol tablet per day will be administrated from 24h post-surgery until bowel movement; for maximum 5 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: inert tablet
Description: one inert tablet will be administrated 2 hours before surgery. One inert tablet per day will be administrated from 24h post-surgery until bowel movement; for maximum 5 days.
Study: NCT03818945

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: shofu PRG barrier coat
Description: Trilaminar structure which forms a type of stable glass ionomer allowing ion release and recharge, while protecting the glass core from the damaging effects of moisture, greatly improving long-term durability.(Na, BO3, Al, SiO3, F,Sr)

Intervention type: DRUG
Group type: OTHER
Intervention: Sodium fluoride varnish
Description: 5% sodium fluoride \[22,600 ppm F-\]
Study: NCT01818856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir withdrawal, atazanavir 200 mg/12h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir interactions
Study: NCT01475838

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PI
Description: PI administered according to prescribing information; allowed PIs include atazanavir (ATV), darunavir (DRV), fosamprenavir (FPV), lopinavir (LPV), or saquinavir (SQV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RTV
Description: RTV administered according to prescribing information FTC/TDF administered according to prescribing information

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TDF
Description: FTC/TDF (200/300 mg) administered according to prescribing information

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stribild
Description: Stribild (E/C/F/TDF) (150/150/200/300 mg) STR administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stribild
Description: Stribild (E/C/F/TDF) (150/150/200/300 mg) STR administered orally once daily with food
Study: NCT03482063

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Swisse Ultiboost Memory + Focus
Description: B vitamins help energy release, help with metabolism of food into energy, assist energy production and vitality.~Vitamin B5 helps support normal mental performance. Brahmi, Ginkgo, Vitamin B12 and B3 help support brain function. Ginkgo helps maintain healthy circulation and delivery of oxygenated blood to the brain.~Brahmi supports memory function and recall. Vitamin B5, B6 are important for adrenal function, assist adrenal glands during stress periods.~Vitamin B2, B3, B5, B6, B12 help relieve tiredness and fatigue.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: riboflavin (2.2mg)
Study: NCT04066361

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chatbot
Description: Interactive text chat designed to mirror the educational components of a traditional genetic counseling visit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Education
Description: Brief video designed to mirror the educational components of a traditional genetic counseling visit
Study: NCT04347837

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Titan SGS stapler
Description: Stapler for the longitudinal resection of the stomach
Study: NCT03913806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab-IRDye800CW
Description: dose finding:10mg; 25mg; 50mg
Study: NCT04012697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Support
Description: Participants randomized to the intervention group will be seen by the peer support worker during their stay in the emergency department. The goal of the peer support worker's practice is to address the participant's wellness from a holistic point of view that includes their relationships, connections to the community, general well-being, and sense of empowerment, with an overall focus on quality-of-life goals (Sunderland et al., 2013). The peer support worker will provide a multi-faceted intervention, which aims to foster a peer-to-peer relationship encompassing elements of empathic communication, brief supportive counseling, advocacy for non-medical needs in hospital, liaising and collaborating with medical and nursing staff, motivational interviewing, and connection with programs in the community.
Study: NCT02945215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI301
Description: IBI301 375mg/㎡

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab 375mg/㎡
Study: NCT02339766

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum Block
Description: Quadratus Lumborum Block with Ropivacaine 0.5% will be done.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum Block
Description: Quadratus Lumborum Block with Ropivacaine 0.5% will be done.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Block
Description: Sham block of Quadratus Lumborum will be done with Saline.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Intrathecal Morphine
Description: Intrathecal Morphine 150 mcg will be co-administered with the spinal anesthetic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Morphine
Description: Intrathecal Morphine 150 mcg will be co-administered with the spinal anesthetic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Saline
Description: Intrathecal Saline 0.15 mL will be co-administered with the spinal anesthetic.